In the trial, patients who received Rydapt in combination with chemotherapy lived longer than patients who received chemotherapy alone, although
a specific median survival rate could not be reliably estimated.
Not exact matches
Statistical analysis was used to determine Overall
Survival (OS), Disease
Specific Survival (DSS) and PSA Failure rates (PSAF), and the
median follow - up was more than 11 years.
The
median progression - free
survival (PFS) from the start of the first HER2 -
specific treatment was 5.1 months.